Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANO-3: Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer
2024-513635-24-00Phase 3Completed
- Sponsor
- Erasmus MC
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nivolumab in esophageal cancer and esophagogastric junction cancer, sponsored by Erasmus MC. Primary endpoint: Disease-free survival. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on 2024-513635-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513635-24-00.